ADCs consist of antibodies, payloads, and chemical linkers. The ideal ADC drug remains stable in the blood circulation, precisely reaches its therapeutic target, and ultimately releases its cytotoxic payload in the vicinity of the target (e.g., cancer cells). Each element affects the ultimate efficacy and safety of the ADC. Therefore, ADC production requires appropriate facilities that strictly adhere to cGMP standards and guidelines for the production of standard biomacromolecules. BOC Sciences has manufacturing sites in the US and UK, supporting a wide range of ADC cGMP manufacturing project needs. We can provide non-cGMP/cGMP pilot and commercial scale solutions for your ADC.
Our production base adopts the international leading design concept, the overall layout is reasonable, the partition is clear, the process flow is smooth, and it can reach the high-efficiency production technology level.
Our R&D team has many years of ADC development experience. We have a proven track record in developing ADC projects over the years. Leveraging our strengths in chemistry, our R&D team has successfully developed and improved dozens of ADCs.
BOC Sciences is also equipped with ADC characterization support services to ensure the purity and quality of the final product. Our professional impurity purification process can remove impurities such as free linkers, antibodies and ADC polymers during ADC purification. In addition, our cGMP process development services cover ADC conjugation strategies, formulations and purification protocol optimization.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
Contact our experts today for pricing and comprehensive details on our ADC offerings.